Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB2 | P05107 | 5/20 | 0.52 |
| ▸ | ICAM1 | P05362 | 5/20 | 0.52 |
| ▸ | ITGAL | P20701 | 5/20 | 0.52 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | PPARG | P37231 | 1/20 | 0.49 |
| ▸ | GPR132 | Q9UNW8 | 4/20 | 0.49 |
| ▸ | ERAP2 | Q6P179 | 1/20 | 0.47 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.47 |
| ▸ | TACR1 | P25103 | 2/20 | 0.47 |
| ▸ | ADAM17 | P78536 | 1/20 | 0.45 |
| ▸ | LNPEP | Q9UIQ6 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1123056 | 0.92 | PPARG (0.54) | ITGB2ICAM1ITGALMEN1KMT2A | |
| SCHEMBL1122844 | 0.91 | MEN1 (0.63) | MEN1KMT2APPARGGPR132ERAP2 | |
| SCHEMBL28757743 | 0.89 | ITGB2 (0.51) | ITGB2ICAM1ITGALMEN1KMT2A | |
| SCHEMBL1123375 | 0.84 | PPARG (0.65) | ITGB2ICAM1ITGALMEN1KMT2A | |
| SCHEMBL1123228 | 0.84 | GPR132 (0.60) | PPARGGPR132 | |
| SCHEMBL1123192 | 0.84 | GPR132 (0.63) | PPARGGPR132 | |
| SCHEMBL1122887 | 0.84 | TACR1 (0.54) | MEN1KMT2APPARGGPR132ERAP2 | |
| SCHEMBL1122929 | 0.82 | PPARG (0.59) | ITGB2ICAM1ITGALMEN1KMT2A | |
| SCHEMBL1123378 | 0.80 | GPR132 (0.57) | GPR132 | |
| SCHEMBL1123431 | 0.78 | GPR132 (0.61) | GPR132 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1644321-B1 | NEW BENZAMIDES AS PPATY MODULATORS | S A L V A T LAB SA (ES) | 2011-02-09 | — | — | EP | disclosed |
| US-20060160894-A1 | Benzamides as ppar modulators | LABORATORIOS S.A.L.V.A.T.,S.A. (ES) | 2006-07-20 | — | — | US | disclosed |
| EP-1644321-A2 | NEW BENZAMIDES AS PPATY MODULATORS | LABORATORIOS S.A.L.V.A.T., S.A. (ES) | 2006-04-12 | — | — | EP | disclosed |
| WO-2004110983-A2 | NEW BENZAMIDES AS PPARϒ MODULATORS | LABORATORIOS S.A.L.V.A.T., S.A. (ES) | 2004-12-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060160894-A1 | Benzamides as ppar modulators | PPARD, PPARA, PPARG | ITGB2 2389/4885ICAM1 3103/4885ITGAL 2297/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.